BFA
RETA

BlackRock Fund Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

BlackRock Fund Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$4.01M Buy
183,797
+30,455
+20% +$770K ﹤0.01% 3003
2016
Q3 		$4.04M Buy
153,342
+6,245
+4% +$124K ﹤0.01% 2938
2016
Q2 		$2.9M Buy
+147,097
New +$2.86M ﹤0.01% 3089

Other funds holding RETA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LFWA
LBJ Family Wealth Advisors Austin, Texas $196M AUM 22.12% 1-Year Est. Return

BlackRock Fund Advisors's RETA Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 20% in Q4 2016, buying an estimated $770K and bringing the position to 183,797 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3003.

BlackRock Fund Advisors first reported a position in RETA in Q2 2016 and has held it in 3 quarters since. The position peaked at $4.04M in Q3 2016. 52 funds tracked by Wall St. Rank hold RETA as of Q4 2016.

  • BlackRock Fund Advisors held 183,797 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $4.01M as of Q4 2016.
  • BlackRock Fund Advisors bought 30,455 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2016, an estimated $770K.
  • Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3003 holding.
  • BlackRock Fund Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Fund Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.04M in Q3 2016.
  • 52 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.